"Pacritinib Curbs Splenomegaly In Some With Myelofibrosis" - David Douglas
In patients with myelofibrosis, pacritinib may offer advantages over best available therapy (BAT) including ruxolitinib, according to findings from a trial truncated due to safety concerns. "Pacritinib represents an alternative JAK inhibitor that can provide clinical benefit to patients with advanced myelofibrosis and baseline thrombocytopenia or as second-line therapy after ruxolitinib failure," said John O. Mascarenhas, MD, associate professor of medicine, hematology and medical oncology, director of the adult leukemia program and leader of the clinical investigation with myeloproliferative disorders program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. He added, "I remain optimistic that the ongoing phase 2 trial evaluating lower doses of pacritinib and further assessing pharmacokinetics will clarify the optimal dose and schedule to administer this agent."
- John O. Mascarenhas, MD, Associate Professor, Medicine, Hematology and Medical Oncology, Director, Adult Leukemia Program, Leader, Clinical Investigation within Myeloproliferative Disorders Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage
Cancer Network
